What smart money is saying about Danaher Corporation
6 funds in our archive have pitched Danaher Corporation — most recently TAMIM Fund Global High Conviction in July 2026.
Danaher Corporation is a diversified global technology and science company that specializes in developing, manufacturing, and distributing a wide array of professional, medical, industrial, and commercial products and services across the world. The organization is structured into three primary operating segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. Within the Life Sciences segment, Danaher provides advanced instrumentation and solutions crucial for scientific research and development. This encompasses equipment like mass spectrometers, flow cytometry, genomics, lab automation, centrifugation, particle counting and characterization tools, and microscopes, alongside genomics consumables and technologies vital for Gene and Cell Therapy. Additionally, it delivers bioprocess technologies, consumables, and related services, as well as sophisticated filtration, separation, and purification systems. Its diverse clientele includes pharmaceutical, biopharmaceutical, food and beverage, medical, and life sciences companies, in addition to universities, medical schools, research institutions, and various industrial manufacturers. The Diagnostics segment is dedicated to furnishing essential tools for healthcare. Its offerings range from comprehensive systems for chemistry, immunoassay, microbiology, and automation to products for hematology, molecular, acute care, and pathology diagnostics. This segment equips hospitals, physicians' offices, reference laboratories, and other critical care settings with clinical instruments, reagents, consumables, software, and support services for accurate patient diagnosis and management. The Environmental & Applied Solutions segment addresses a broad spectrum of industrial and resource management requirements. It supplies instrumentation, consumables, software, services, and disinfection systems critical for the analysis, treatment, and management of various water types—including ultra-pure, potable, industrial, waste, ground, source, and ocean water—across residential, commercial, industrial, and natural resource applications. Furthermore, this segment delivers instruments, software, services, and consumables tailored for color and appearance management, packaging design and quality assurance, packaging converting, printing, marking, coding, and traceability applications for consumer, pharmaceutical, and industrial products. Established in 1969, the company was initially known as Diversified Mortgage Investors, Inc., before officially rebranding as Danaher Corporation in 1984. Its corporate headquarters are located in Washington, D.C.
Get an email when a fund writes about it
Position history
Between Q2 2025 and Q3 2026, 18 fund letters reported a position in Danaher Corporation — 7 opened or added to the position, 5 trimmed or exited.
| Quarter | Letters | Bought | Sold | Theses |
|---|---|---|---|---|
| Q3 2026 | 2 | 1 | 0 | 1 |
| Q2 2026 | 14 | 5 | 5 | 2 |
| Q1 2026 | 2 | 1 | 0 | 1 |
| Q4 2025 | 0 | 0 | 0 | 1 |
| Q2 2025 | 0 | 0 | 0 | 1 |
Fund activity · 18 positions · 12 moves
- July 2026
“Danaher Corporation (NYSE: DHR) Danaher (NYSE: DHR) is the compounding machine of the three.”
Danaher Corporation - July 2026
“Danaher: A minor disappointment in Biotechnology but improving underlying markets Danaher also reported its second-quarter results during the month. The report beat market expectations on both revenue and earnings per share. The disappointment lay instead in the performance of the company's most important segment, Biotechnology, which came in below expectations, sending the Danaher share down by more than 15% during the day. The dominant explanation is that a couple of larger orders for major customers, scheduled for delivery in the second and third quarters, are instead being pushed into 2027 as a result of facility and scheduling issues at those customers. As a result, Danaher lowered its full-year guidance. Since the growth narrative sits within Biotechnology, which also carries higher profitability than the group as a whole, the impact is amplified. Underlying order intake for Biotechnology nevertheless remained strong, growing by around 15% for both equipment and key consumables. This is the second consecutive quarter of rapid order growth. The positive trend in Bioprocessing was also confirmed by Thermo Fisher, which said that the improved customer activity in biotech is now beginning to translate into actual revenue, and which raised its full-year guidance. A further data point supporting this thesis came recently from US-based Repligen, whose business consists 100% of Bioprocessing (equipment and consumables). As the fund has noted previously, the company often serves as a good indicator, since its order intake is a pure measure of Danaher's and Thermo Fisher's most important growth engine. During the second quarter, book-to-bill improved sharply sequentially and was said to be clearly above 1.0x, while the order book is being built up ahead of 2027. Order trends are strong overall, and China has improved markedly (+60% in the first half), accounting for 8–10% of Thermo's and Danaher's respective revenue. There is also growing discussion around reshoring production. Repligen has won several large capacity expansion projects and, according to the company, is “on track to win a third within the coming weeks”, which confirms that this investment cycle is also under way. The fund increased its holding in Danaher on the day of the report, as the share price decline was judged to be excessive.”
Danaher Corporation - June 2026
“During the quarter, we initiated new investments in ASML Holding (ASML) and we exited our position in Intuit (INTU). During the quarter-end rebalance of the Quality Premier strategy, we also exited Ametek (AME), added to our holdings in Broadcom (AVGO) and GE Vernova (GEV), and trimmed Alphabet (GOOG), Amazon (AMZN), Danaher (DHR), and Unilever (UL).”
Danaher Corporation - ExitedMD SASS Concentrated ValueJune 2026
“During the quarter, we also exited our positions in Aon (AON), CBRE Group (CBRE), Danaher (DHR), Gildan Activewear (GIL), Quanta Services (PWR), and Synopsys (SNPS).”
Danaher Corporation - June 2026
Listed in Harding Loevner Global Equity’s reported holdings.
Danaher Corporation Listed in Sustainable Growth Advisers U.S. Large Cap Growth Strategy’s reported holdings.
Danaher Corporation- June 2026
“Recent Portfolio Activity During the quarter, we sold our positions in Atmos Energy and Danaher and purchased Autodesk and Edwards Lifesciences.”
Danaher Corporation - June 2026
“Health Care increased during the quarter. Price appreciation from UnitedHealth Group Inc (UNH) increased the weighting, and we added to Danaher Inc (DHR).”
Danaher Corporation - June 2026
“Recent Portfolio Activity During the quarter, we sold our positions in Atmos Energy and Danaher and purchased Autodesk and Edwards Lifesciences.”
Danaher Corporation - June 2026
“We added materially to existing holdings on the same logic: Apple’s share count rose c.90% (now the Fund’s largest position at 5.4%), Danaher, Thermo Fisher, L’Oréal and Ferrari were all more than doubled, and Lilly, Amazon, Alphabet and Meta increased.”
Danaher Corporation - June 2026
“We added materially to existing holdings on the same logic: Apple’s share count rose c.90% (now the Fund’s largest position at 5.4%), Danaher, Thermo Fisher, L’Oréal and Ferrari were all more than doubled, and Lilly, Amazon, Alphabet and Meta increased.”
Danaher Corporation - June 2026
“During the quarter, we sold our positions in Danaher, Dolby Laboratories, and Tokyo Century and purchased Techtronic Industries and Wal-Mart de Mexico.”
Danaher Corporation - June 2026
“Trading Activity 2Q During the quarter we added to the Fund’s positions in Danaher, Thermo Fisher Scientific, and Martin Marietta Materials at prices we think offer substantial upside with favorable risk profiles.”
Danaher Corporation - June 2026
“Portfolio activity beyond the entries and exits above was more muted and tilted toward trims. Beyond the exits of Accenture and Salesforce, we also trimmed our holdings of Alphabet, Amazon, Bio-Techne, SiriusXM and Thermo Fisher, partially offset by additions to Danaher and Global Payments.”
Danaher Corporation - HoldsFPA Crescent FundJune 2026
Listed in FPA Crescent Fund’s reported holdings.
Danaher Corporation - May 2026
Listed in Kavaljer Investmentbolagsfond’s reported holdings.
Danaher Corporation - March 2026
“During the quarter-end rebalance of the Quality Premier strategy, we added to our holdings in Danaher (DHR), Netflix (NFLX) and Linde plc (LIN), and trimmed Intuit (INTU) and Meta Platforms (META).”
Danaher Corporation - March 2026
“We’ve built a position in Danaher, a leading life sciences company.”
Danaher Corporation
Also mentioned · 4
These funds discuss Danaher Corporation — as a competitor, benchmark or comparable — without disclosing a position in it.
- MentionedRewey AM RAM Smid Value CompositeJune 2026
“Vontier (VNT) We initiated a position in Vontier Corp. (NYSE: VNT), a $4.2 billion industrial technology company that provides fueling equipment, payment systems, and automotive repair tools. Although Vontier became an independent company only after its 2020 spin-off from Fortive (itself spun from Danaher in 2016), its portfolio includes well-established brands such as Gilbarco Veeder-Root and Matco.”
Danaher Corporation - MentionedDiamond Hill Long-Short FundJune 2026
“• Water testing and treatment provider Veralto was spun out of Danaher in late 2023.”
Danaher Corporation - MentionedFPA Queens Road Small Cap Value FundJune 2026
“The company was spun off from Fortive in 2021; Fortive itself was spun off from Danaher's lower- growth industrial businesses.”
Danaher Corporation - March 2026
“At the sector level, the Strategy’s overweight to Industrials and Materials had positive effects, largely offsetting the negative impact of our underweight to Consumer Staples and overweight to Financials. Stock selection was the biggest driver of the Strategy’s relative underperformance for the quarter, particularly in Industrials, Health Care and Financials. Within Industrials, strong performance from Carrier Global was not enough to make up for the underperformance of Verisk Analytics (which we exited during the quarter) and Equifax (EFX). In addition, certain defense stocks which are in the Index but not held in the strategy hurt relative performance. In Health Care, both Intuitive Surgical (ISRG) and Danaher Corp (DHR) were negative relative contributors despite improving and solid fundamental performance.”
Danaher Corporation
Fund coverage · 6 theses
- TAMIM Fund Global High ConvictionJuly 2026
Danaher is a high-quality life sciences and diagnostics compounder with reaccelerating growth, strong margins and disciplined ownership.
Read the full thesis - Aristotle Global Equity AdvisoryJune 2026
Danaher is a disciplined healthcare platform with recurring revenue, strong capital allocation, and a culture that supports margin expansion and free cash flow.
Read the full thesis - Kavaljer InvestmentbolagsfondMay 2026
Danaher is a recurring-revenue life science and diagnostics compounder with improving bioprocessing demand, AI tailwinds, and a discounted valuation.
Read the full thesis - Eagle Capital ManagementMarch 2026
Danaher is a leading life sciences company with high share, strong management, and improving growth prospects.
Read the full thesis - Baron Durable Advantage FundDecember 2025
Danaher is a high-quality life sciences and diagnostics tools provider poised to benefit from reshoring capex, improving funding trends, and structural strengths to drive double-digit EPS growth.
Read the full thesis - Baron Durable Advantage FundJune 2025
Danaher Corporation is a quality compounder in the life sciences sector, well-positioned for long-term growth in bioprocessing despite current market pressures.
Read the full thesis
Read every full thesis on Danaher Corporation
Unlock all 6 theses — the full reasoning behind what funds are buying, plus unlimited access to the entire archive.
View plans→